tiprankstipranks
Advertisement
Advertisement

EBR Systems names Philip Oettinger as new U.S. Corporate Secretary

Story Highlights
  • EBR Systems has replaced John Sellers with Philip Oettinger as its U.S. Corporate Secretary, marking a governance refresh following its ASX listing.
  • Oettinger’s extensive life sciences and capital markets experience is expected to bolster EBR Systems’ regulatory, transactional and commercialization efforts for its WiSE pacing technology.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
EBR Systems names Philip Oettinger as new U.S. Corporate Secretary

Claim 55% Off TipRanks

EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ) has provided an announcement.

EBR Systems has appointed Philip Oettinger as its U.S. Corporate Secretary, succeeding John Sellers, who has served in the role since the company’s ASX listing. The board acknowledged Sellers’ contributions while signalling a governance refresh that aligns with the company’s ongoing public-market obligations.

Oettinger, a partner in the life sciences practice at Wilson Sonsini Goodrich & Rosati, brings extensive experience advising medical device, biotech, pharma and digital health companies on corporate governance, capital markets and M&A. His appointment is likely to strengthen EBR Systems’ regulatory and transactional capabilities as it advances commercialization of its WiSE wireless cardiac pacing technology and navigates U.S. securities and reporting requirements.

The most recent analyst rating on (AU:EBR) stock is a Hold with a A$0.79 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.

More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

EBR Systems, Inc. is a Silicon Valley-based medical technology company focused on treating cardiac rhythm disease through wireless cardiac pacing solutions. Its patented Wireless Stimulation Endocardially (WiSE) technology eliminates traditional pacing leads by using an endocardial implant to stimulate the heart’s left ventricle, initially targeting heart failure patients needing Cardiac Resynchronisation Therapy, with potential future applications in bradycardia and other indications.

Average Trading Volume: 485,995

Technical Sentiment Signal: Sell

Current Market Cap: A$332.9M

See more data about EBR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1